Inclusion Criteria:

- Patients with histologically confirmed, surgically incurable or unresectable stage
IIIc or IV melanoma, including ocular melanoma.

- Patients must not have received prior chemotherapy for melanoma, excluding
chemotherapy given during isolated limb perfusion for stage IIIc melanoma. Patients
who received adjuvant immunotherapy and/or immunotherapy for metastatic disease are
eligible for the trial.

- ECOG of 0-2.

- Age >= 18 years.

- Adequate laboratory values performed within 28 days prior to initiation of dosing.

- Absolute neutrophil count (ANC) >=1500/uL

- Platelet count >=100,000/uL

- Hemoglobin >=10.0 g/dL

- Serum creatinine ≤ 2 times ULN

- Total serum bilirubin <= 2 times ULN

- LDH <= 5 times ULN

- AST/SGOT or ALT/SGPT <= 2.5 times ULN, and <= 5 times ULN in cases of liver
metastasis

- Patients must have recovered from effects of major surgery or other prior therapy,
which should have been completed at least 28 days before starting experimental
therapy.

- Women of childbearing potential should be using an effective method of contraception.
Women of childbearing potential must have a negative urine or serum pregnancy test up
to 28 days prior to commencement of dosing and be practicing medically approved
contraceptive precautions for at least 6 months after completion of treatment as
directed by their physician.

- Men should use an effective method of contraception during treatment and for at least
6 months after completion of treatment as directed by their physician.

Exclusion Criteria:

- Major surgery, radiation therapy or immunotherapy within 4 weeks of starting the
study treatment.

- Evidence of active brain metastases.

- Any of the following within the 12 months prior to study drug administration:
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
graft, symptomatic congestive heart failure, cerebrovascular accident or transient
ischemic attack, or pulmonary embolism.

- Ongoing cardiac dysrhythmias of NCI CTCAE Version 3.0 grade >= 2.

- Prolonged QTc interval on baseline EKG.

- Left ventricular ejection fraction less than 50% on screening echocardiogram

- Uncontrolled hypertension (>150/100 mm Hg despite optimal medical therapy).

- Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
the normal range with medication.

- Treatment with drugs with dysrhythmic potential

- Treatment with potent CYP3A4 inhibitors and inducers

- Known clinically uncontrolled infectious disease including HIV positivity or
AIDS-related illness.

- Pregnant or nursing.